These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 29403308)

  • 21. Role of the cGAS-STING pathway in regulating the tumor-immune microenvironment in dMMR/MSI colorectal cancer.
    Kaneta A; Nakajima S; Okayama H; Matsumoto T; Saito K; Kikuchi T; Endo E; Ito M; Mimura K; Kanke Y; Saito M; Saze Z; Fujita S; Sakamoto W; Onozawa H; Momma T; Ohki S; Kono K
    Cancer Immunol Immunother; 2022 Nov; 71(11):2765-2776. PubMed ID: 35429245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of Programmed Death Ligand 1 [PD-L1] and Mismatch Repair Status in Squamous Cell Carcinomas of Cervix.
    Anju G; Rao M; Elhence PA; Nalwa A; Singh P; Yadav G; Goel AD; Thiruvengadam D
    J Obstet Gynaecol India; 2024 Aug; 74(4):319-325. PubMed ID: 39280198
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mismatch repair proteins expression and tumor-infiltrating T-cells in colorectal cancer.
    Shigaki T; Fujiyoshi K; Sudo T; Kawahara A; Nakane H; Yomoda T; Nagasu S; Kinugasa T; Akiba J; Fujita F; Akagi Y
    Oncol Lett; 2022 Nov; 24(5):396. PubMed ID: 36276483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Predictive markers of immunotherapy in cervical cancer].
    Oliushina EM; Zavalishina LE; Andreeva YY; Kuznetsova OA; Moskvina LV; Frank GA
    Arkh Patol; 2023; 85(5):5-12. PubMed ID: 37814844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a systematic review and meta-analysis.
    Han S; Guo C; Song Z; Ouyang L; Wang Y
    Front Pharmacol; 2023; 14():1330877. PubMed ID: 38161705
    [No Abstract]   [Full Text] [Related]  

  • 26. [Analysis of microsatellite instability in endometroid carcinoma with deficient mismatch repair].
    Zhang YH; Wu HW; Wang J; Liang ZY
    Zhonghua Bing Li Xue Za Zhi; 2021 May; 50(5):470-475. PubMed ID: 33915653
    [No Abstract]   [Full Text] [Related]  

  • 27. Circulating Lymphocytes, PD-L1 Expression on Tumor-infiltrating Lymphocytes, and Survival of Colorectal Cancer Patients with Different Mismatch Repair Gene Status.
    Kong P; Wang J; Song Z; Liu S; He W; Jiang C; Xie Q; Yang L; Xia X; Xia L
    J Cancer; 2019; 10(7):1745-1754. PubMed ID: 31205530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer.
    Wu X; Lan X; Hu W; Zhang W; Lai X; Xu S; Li J; Qiu W; Wang W; Xiao J; Wang F; Ding Y; Liang L
    Cancer Immunol Immunother; 2021 Nov; 70(11):3235-3248. PubMed ID: 33818637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy.
    Kim ST; Klempner SJ; Park SH; Park JO; Park YS; Lim HY; Kang WK; Kim KM; Lee J
    Oncotarget; 2017 Sep; 8(44):77415-77423. PubMed ID: 29100397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PD-1/PD-L1 Inhibitors Monotherapy for the Treatment of Endometrial Cancer: Meta-Analysis and Systematic Review.
    Dai Y; Muaibati M; Xie W; Abasi A; Li K; Tong Q; Zhang T; Meng Y; Zhuang L; Huang X
    Cancer Invest; 2022 Mar; 40(3):293-309. PubMed ID: 34825855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma.
    Lee HK; Kwon MJ; Ra YJ; Lee HS; Kim HS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Min KW; Kang SY
    Diagn Pathol; 2020 Oct; 15(1):126. PubMed ID: 33054840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Programmed Death-Ligand 1 Expression on Mismatch Repair Deficiency and Epstein-Barr Virus Status on Survival Outcomes in Patients with Stage II/III Gastric Cancer After Surgery.
    Akimoto E; Kuwata T; Shitara K; Kawazoe A; Sakamoto N; Ishii G; Ochiai A; Kinoshita T
    Ann Surg Oncol; 2023 Aug; 30(8):5227-5236. PubMed ID: 36934377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial.
    Antill Y; Kok PS; Robledo K; Yip S; Cummins M; Smith D; Spurdle A; Barnes E; Lee YC; Friedlander M; Baron-Hay S; Shannon C; Coward J; Beale P; Goss G; Meniawy T; Lombard J; Andrews J; Stockler MR; Mileshkin L;
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34103352
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer.
    Yang Z; Wu G; Zhang X; Gao J; Meng C; Liu Y; Wei Q; Sun L; Wei P; Bai Z; Yao H; Zhang Z
    Front Immunol; 2022; 13():1001444. PubMed ID: 36159842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Association of status of mismatch repair protein expression and EB virus infection with clinicopathological parameters in 886 gastric adenocarcinoma patients].
    Liu Y; Zang FL; Qiu ZQ; Guo YH; Luo Y; Sun L; Zhao S; Shao B; Liang H; Sun Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May; 24(5):440-448. PubMed ID: 34000774
    [No Abstract]   [Full Text] [Related]  

  • 36. Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes.
    Williams DS; Mouradov D; Jorissen RN; Newman MR; Amini E; Nickless DK; Teague JA; Fang CG; Palmieri M; Parsons MJ; Sakthianandeswaren A; Li S; Ward RL; Hawkins NJ; Faragher I; Jones IT; Gibbs P; Sieber OM
    Gut; 2019 Mar; 68(3):465-474. PubMed ID: 29382774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors.
    Hollebecque A; Chung HC; de Miguel MJ; Italiano A; Machiels JP; Lin CC; Dhani NC; Peeters M; Moreno V; Su WC; Chow KH; Galvao VR; Carlsen M; Yu D; Szpurka AM; Zhao Y; Schmidt SL; Gandhi L; Xu X; Bang YJ
    Clin Cancer Res; 2021 Dec; 27(23):6393-6404. PubMed ID: 34465599
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stage-dependent prognostic shift in mismatch repair-deficient tumors: Assessing patient outcomes in stage II and III colon cancer.
    Hestetun KE; Rosenlund NB; Stanisavljević L; Dahl O; Myklebust MP
    Front Oncol; 2022; 12():853545. PubMed ID: 36110945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair.
    Alex AK; Siqueira S; Coudry R; Santos J; Alves M; Hoff PM; Riechelmann RP
    Clin Colorectal Cancer; 2017 Sep; 16(3):228-239. PubMed ID: 28063788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Mechanisms Leading to Distinct Responses to PD-1/PD-L1 Blockades in Colorectal Cancers With Different MSI Statuses.
    Cui G
    Front Oncol; 2021; 11():573547. PubMed ID: 33763344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.